Earnings Feed
Sign Up
Home/Filings/4/0001104659-19-064171
4//SEC Filing

CELGENE CORP /DE/ 4

Accession 0001104659-19-064171

CIK 0001439222operating
View on SEC.govCompany Profile

Filed

Nov 13, 7:00 PM ET

Accepted

Nov 14, 4:06 PM ET

Size

12.9 KB

Accession

0001104659-19-064171

Insider Transaction Report

Form 4
Period: 2019-11-12
AGIOS PHARMACEUTICALS, INC.AGIO
Celgene European Investment Co LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2019-11-12$31.00/sh+403,225$12,499,975→ 1,777,824 total
Holdings

  • Common Stock

    (indirect: See footnote)
    624,575

  • Common Stock

    (indirect: See footnote)
    4,010,926

  • Common Stock

    (indirect: See footnote)
    708,333
Celgene Switzerland LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2019-11-12$31.00/sh+403,225$12,499,975→ 1,777,824 total
Holdings

  • Common Stock

    (indirect: See footnote)
    624,575

  • Common Stock

    (indirect: See footnote)
    4,010,926

  • Common Stock

    (indirect: See footnote)
    708,333
CELGENE CORP /DE/
10% Owner
Transactions
  • Purchase

    Common Stock

    2019-11-12$31.00/sh+403,225$12,499,975→ 1,777,824 total
Holdings

  • Common Stock

    (indirect: See footnote)
    624,575

  • Common Stock

    (indirect: See footnote)
    708,333

  • Common Stock

    (indirect: See footnote)
    4,010,926
Celgene Alpine Investment Co., LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2019-11-12$31.00/sh+403,225$12,499,975→ 1,777,824 total
Holdings

  • Common Stock

    (indirect: See footnote)
    624,575

  • Common Stock

    (indirect: See footnote)
    708,333

  • Common Stock

    (indirect: See footnote)
    4,010,926
Footnotes (3)
  • [F1]Owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
  • [F2]Owned directly by Celgene European Investment Company LLC, a wholly-owned subsidiary of Celgene. Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
  • [F3]Owned directly by Celgene Alpine Investment Co., LLC, a wholly-owned subsidiary of Celgene. Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Documents

1 file

Issuer

AGIOS PHARMACEUTICALS, INC.

CIK 0001439222

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000816284

Filing Metadata

Form type
4
Filed
Nov 13, 7:00 PM ET
Accepted
Nov 14, 4:06 PM ET
Size
12.9 KB
View on SEC.gov